MedTrace Logo

The Impact of Mentor Mothers on PMTCT Service Outcomes in Nigeria

NCT01936753 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 497

Last updated 2018-09-18

No results posted yet for this study

Summary

Nigeria has significant challenges in the delivery and coverage of PMTCT (Prevention of mother-to-child transmission of HIV) services. Only 30% of pregnant women living with HIV are provided anti-retroviral drugs for PMTCT. Less than 10% of HIV-exposed infants receive HIV testing for early diagnosis by age 2 months. Furthermore, an unacceptably high number of women with HIV who are enrolled in PMTCT programs do not complete them. In other words, uptake and retention in PMTCT programs in Nigeria is not adequate. Ultimately, mother-to-child transmission of HIV is high, resulting in a high number of new child HIV infections.

Mentor Mothers (MMs) are women living with HIV who provide peer support to other HIV-positive women. MM programs have been incorporated into PMTCT programs in several African countries with some success, but with varying levels of MM training and program structure. The MoMent (MOther MENTor) study investigates whether highly-structured MM programs will further improve uptake and successful completion of PMTCT services (eg testing and appointments) in Nigeria. The study also evaluates the impact of structured MM programs on other outcomes, including facility deliveries, new infant HIV infections, infant survival and maternal viral suppression. Rural areas are the focus of this study because of their particularly poor performance in PMTCT coverage and outcomes.

Conditions

Interventions

BEHAVIORAL

Trained Mentor Mother and Supervisor

Trained, closely supervised Mentor Mothers guide and support the mother-infant pair to achieve timely and complete access to, and retention in PMTCT services along the entire cascade.

Sponsors & Collaborators

  • University of Maryland

    collaborator OTHER

  • Federal Ministry of Health, Nigeria

    collaborator OTHER_GOV

  • Institute of Human Virology, Nigeria

    lead OTHER

Principal Investigators

  • Nadia A Sam-Agudu, MD, CTropMed · Institute of Human Virology, Nigeria; University of Maryland School of Medicine

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
15 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-24
Primary Completion
2016-11-30
Completion
2017-11-01

Countries

  • Nigeria

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01936753 on ClinicalTrials.gov